MedTrace Logo

Clinical Pathway for Alzheimer's Disease in China (CPAD)

NCT01779310 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1024

Last updated 2017-07-25

No results posted yet for this study

Summary

There are guidelines on the management of AD in China, the evidence adopted in the guidelines are mostly from the trials conducted in other countries due to very limited Chinese data available for local systematic review. Therefore, more local evidence on dementia care is needed for the development of an evidence-based guideline appropriate for people living in China. Meanwhile, the inadequate implementation of the current AD guideline, which results in the low diagnostic rate and high diagnostic leakage, may bring about extra barriers for AD patients to access dementia care service in different areas nationwide. However, there is no data on the clinical pathway about how physicians follow the dementia guideline in the routine practice.

Therefore, research is needed to learn clinical diagnostic process and treatment patterns of physicians to people with AD in routine practice and help address the low accurate rate of AD clinical diagnosis and low anti-dementia drug prescription in the real world and support guideline development.

Conditions

Sponsors & Collaborators

  • Beijing Novartis Pharma

    collaborator INDUSTRY

  • Peking University

    lead OTHER

Principal Investigators

  • Huali Wang, MD/PhD · Peking University Institute of Mental Health (Sixth Hospital)

Eligibility

Min Age
45 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-11-30
Primary Completion
2013-04-30
Completion
2013-04-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01779310 on ClinicalTrials.gov